Orris

Management of bronchial asthma acc to latest standard guidelines and harrison

Reading File
Finding Sources
Searching PubMed

"asthma"[MeSH Terms] AND "management" AND "guidelines"

Searching the Web

GINA 2025 2026 asthma management guidelines latest update

Finding Sources
Reading Web Page

https://www.guidelinecentral.com/insights/may-2026-gina-asth…

Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Searching Images

asthma stepwise management GINA treatment steps inhaler

Summary : This figure presents the 2021 Asthma Management Continuum for preschoolers, children, and adults, outlining a stepwise approach to asthma therapy based on severity and age, with regular reassessment and escalation of treatment as needed. flowchart: # Main Structure : • The continuum is depicted as a sloped, color-coded triangle progressing from bottom left (mild) to top right (severe). • The base includes foundational steps, with increasing therapy intensity as you move upward. # Steps and Nodes : • Confirm Diagnosis (bottom, blue bar) • Environmental Control, Education and Written Action Plan (above, teal bar) • SABA or bud/form* as needed (grey bar) • Inhaled Corticosteroid (ICS) (large yellow-green area, central) – Second-Line: Leukotriene Receptor Antagonist (LTRA) – ICS Dosing: • Low Dose: – ≥12 yrs: ≤250 mcg/day § – 6-11 yrs: ≤200 mcg/day § – 1-5 yrs: <200 mcg/day § • Medium Dose: – ≥12 yrs: 251–500 mcg/day § – 6-11 yrs: 201–400 mcg/day § – 1-5 yrs: 200–250 mcg/day § • High Dose: – ≥12 yrs: >500 mcg/day § – 6-11 yrs: >400 mcg/day § – 1-5 yrs: Refer • Add-on therapies (upper right, color-coded by age group): – ≥12 yrs: Add LABA, then LTRA and/or tiotropium – 6-11 yrs: Add LABA or LTRA – 1-11 yrs: Increase ICS • Severe Asthma (top right, red): Add LTRA and/or tiotropium for ≥12 yrs # Regular Reassessment Box (left side) : • Control • Risk of exacerbation • Spirometry or PEF • Inhaler technique • Adherence • Triggers • Comorbidities • Sputum eosinophils # Connectors and Flow : • Large grey arrow labeled “Adjust Therapy to Achieve Control and Prevent Future Risk” runs diagonally upward, indicating escalation. • Steps are arranged from foundational (bottom) to advanced (top right). # Design Encodings : • Color gradient from blue (mild) to red (severe). • Age groups and therapy steps are color-coded. • Text boxes and arrows guide progression and reassessment. # Analysis : • The figure emphasizes a stepwise, age-specific approach to asthma management, starting with diagnosis and environmental control, then escalating pharmacologic therapy as needed. • Regular reassessment is highlighted as essential at all stages. • The structure supports individualized therapy adjustment based on control and risk, with clear escalation pathways for increasing severity.

Summary : This figure presents the 2021 Asthma Management Continuum for preschoolers, children, and adults, outlining a stepwise approach to asthma therapy based on severity and age, with regular reassessment and escalation of treatment as needed. flowchart: # Main Structure : • The continuum is depicted as a sloped, color-coded triangle progressing from bottom left (mild) to top right (severe). • The base includes foundational steps, with increasing therapy intensity as you move upward. # Steps and Nodes : • Confirm Diagnosis (bottom, blue bar) • Environmental Control, Education and Written Action Plan (above, teal bar) • SABA or bud/form* as needed (grey bar) • Inhaled Corticosteroid (ICS) (large yellow-green area, central) – Second-Line: Leukotriene Receptor Antagonist (LTRA) – ICS Dosing: • Low Dose: – ≥12 yrs: ≤250 mcg/day § – 6-11 yrs: ≤200 mcg/day § – 1-5 yrs: <200 mcg/day § • Medium Dose: – ≥12 yrs: 251–500 mcg/day § – 6-11 yrs: 201–400 mcg/day § – 1-5 yrs: 200–250 mcg/day § • High Dose: – ≥12 yrs: >500 mcg/day § – 6-11 yrs: >400 mcg/day § – 1-5 yrs: Refer • Add-on therapies (upper right, color-coded by age group): – ≥12 yrs: Add LABA, then LTRA and/or tiotropium – 6-11 yrs: Add LABA or LTRA – 1-11 yrs: Increase ICS • Severe Asthma (top right, red): Add LTRA and/or tiotropium for ≥12 yrs # Regular Reassessment Box (left side) : • Control • Risk of exacerbation • Spirometry or PEF • Inhaler technique • Adherence • Triggers • Comorbidities • Sputum eosinophils # Connectors and Flow : • Large grey arrow labeled “Adjust Therapy to Achieve Control and Prevent Future Risk” runs diagonally upward, indicating escalation. • Steps are arranged from foundational (bottom) to advanced (top right). # Design Encodings : • Color gradient from blue (mild) to red (severe). • Age groups and therapy steps are color-coded. • Text boxes and arrows guide progression and reassessment. # Analysis : • The figure emphasizes a stepwise, age-specific approach to asthma management, starting with diagnosis and environmental control, then escalating pharmacologic therapy as needed. • Regular reassessment is highlighted as essential at all stages. • The structure supports individualized therapy adjustment based on control and risk, with clear escalation pathways for increasing severity.

Summary : This figure presents two flowcharts outlining the pharmacological management of chronic obstructive pulmonary disease (COPD) based on the primary symptom: dyspnea or exacerbations. It details stepwise treatment escalation, decision points based on blood eosinophil counts, and additional therapeutic options. flowchart: # Dyspnea Management : Nodes : • LABA or LAMA (rounded rectangle) • LABA + LAMA* (rounded rectangle) • Consider switching inhaler device or molecules; Implement or escalate non-pharmacological treatment(s); Consider adding ensifentrine; Investigate (and treat) other causes of dyspnea (large rounded rectangle) Connectors : • Downward arrows from LABA or LAMA → LABA + LAMA* → management options box Layout : • Vertical, single branch, two main steps followed by a box with four bullet points # Exacerbations Management : Nodes : • LABA or LAMA (rounded rectangle) • LABA + LAMA* (rounded rectangle) • LABA + LAMA + ICS* (rounded rectangle) • Roflumilast (rounded rectangle, “FEV1 < 50% & chronic bronchitis”) • Azithromycin (rounded rectangle, “preferentially in former smokers”) • Dupilumab (rounded rectangle, “chronic bronchitis”) Connectors : • LABA or LAMA → LABA + LAMA* (if blood eos < 300) • LABA or LAMA → LABA + LAMA + ICS* (if blood eos ≥ 300) • LABA + LAMA* → LABA + LAMA + ICS* (if blood eos ≥ 100) • LABA + LAMA + ICS* → Roflumilast, Azithromycin, Dupilumab (branching arrows) • LABA + LAMA + ICS* → Dupilumab (if blood eos ≥ 300) Layout : • Vertical with multiple branches based on blood eosinophil count thresholds (<100, <300, ≥100, ≥300) • Final step branches into three parallel options # Additional Information : • Footnote: Single inhaler therapy may be more convenient and effective than multiple inhalers; single inhalers improve adherence to treatment. • Consider de-escalation of ICS if pneumonia or other considerable side-effects. In case of blood eos ≥ 300 cells/μl de-escalation is more likely to be associated with the development of exacerbations. • Exacerbations refers to the number of exacerbations per year. # Analysis : • The dyspnea pathway is linear, focusing on escalation and device/molecule switching, with consideration for non-pharmacological treatments and other causes. • The exacerbation pathway is more complex, with branching based on blood eosinophil counts, leading to different combinations of inhaled therapies and add-on treatments for specific patient subgroups (chronic bronchitis, former smokers, high eosinophil counts). • The figure emphasizes personalized treatment escalation and the importance of blood eosinophil count in guiding therapy for COPD exacerbations.

Summary : This figure presents two flowcharts outlining the pharmacological management of chronic obstructive pulmonary disease (COPD) based on the primary symptom: dyspnea or exacerbations. It details stepwise treatment escalation, decision points based on blood eosinophil counts, and additional therapeutic options. flowchart: # Dyspnea Management : Nodes : • LABA or LAMA (rounded rectangle) • LABA + LAMA* (rounded rectangle) • Consider switching inhaler device or molecules; Implement or escalate non-pharmacological treatment(s); Consider adding ensifentrine; Investigate (and treat) other causes of dyspnea (large rounded rectangle) Connectors : • Downward arrows from LABA or LAMA → LABA + LAMA* → management options box Layout : • Vertical, single branch, two main steps followed by a box with four bullet points # Exacerbations Management : Nodes : • LABA or LAMA (rounded rectangle) • LABA + LAMA* (rounded rectangle) • LABA + LAMA + ICS* (rounded rectangle) • Roflumilast (rounded rectangle, “FEV1 < 50% & chronic bronchitis”) • Azithromycin (rounded rectangle, “preferentially in former smokers”) • Dupilumab (rounded rectangle, “chronic bronchitis”) Connectors : • LABA or LAMA → LABA + LAMA* (if blood eos < 300) • LABA or LAMA → LABA + LAMA + ICS* (if blood eos ≥ 300) • LABA + LAMA* → LABA + LAMA + ICS* (if blood eos ≥ 100) • LABA + LAMA + ICS* → Roflumilast, Azithromycin, Dupilumab (branching arrows) • LABA + LAMA + ICS* → Dupilumab (if blood eos ≥ 300) Layout : • Vertical with multiple branches based on blood eosinophil count thresholds (<100, <300, ≥100, ≥300) • Final step branches into three parallel options # Additional Information : • Footnote: Single inhaler therapy may be more convenient and effective than multiple inhalers; single inhalers improve adherence to treatment. • Consider de-escalation of ICS if pneumonia or other considerable side-effects. In case of blood eos ≥ 300 cells/μl de-escalation is more likely to be associated with the development of exacerbations. • Exacerbations refers to the number of exacerbations per year. # Analysis : • The dyspnea pathway is linear, focusing on escalation and device/molecule switching, with consideration for non-pharmacological treatments and other causes. • The exacerbation pathway is more complex, with branching based on blood eosinophil counts, leading to different combinations of inhaled therapies and add-on treatments for specific patient subgroups (chronic bronchitis, former smokers, high eosinophil counts). • The figure emphasizes personalized treatment escalation and the importance of blood eosinophil count in guiding therapy for COPD exacerbations.

Summary : This flowchart outlines the evaluation and management process for patients with Sjögren’s syndrome who present with signs and/or symptoms of airway disorders, including recommended diagnostic steps and treatment options. flowchart: # Nodes : • “Sjögren’s patient with signs and/or symptoms of airway disorders” (rounded rectangle, top) • “Obtain PFTs and HRCT” (rounded rectangle) • “Airways disorder” (rounded rectangle) • Treatment options (rectangle with numbered list): 1. Asthma/COPD: Manage as per clinical practice guidelines. Inhaled corticosteroids and beta-agonists are the mainstay of management. Avoid anticholinergics to prevent drying of secretions. 2. Bronchiolitis: Trial of inhaled corticosteroids ± macrolides. 3. Nebulized saline and secretagogues in patients with concern for xerotrachea. • “Annual PFTs” (rounded rectangle, bottom) # Connectors : • Downward arrows connect each node sequentially from top to bottom. • No branching; all steps are linear. # Layout : • Vertical, single-column arrangement. • All nodes are aligned centrally, with the treatment options node larger to accommodate the list. # Analysis : • The flowchart presents a stepwise, linear approach for managing airway disorders in Sjögren’s patients: initial assessment, diagnostic testing, confirmation of disorder, tailored treatment based on specific airway condition, and ongoing annual monitoring. No decision branches or alternative pathways are depicted; the process is straightforward and protocol-driven.

Summary : This flowchart outlines the evaluation and management process for patients with Sjögren’s syndrome who present with signs and/or symptoms of airway disorders, including recommended diagnostic steps and treatment options. flowchart: # Nodes : • “Sjögren’s patient with signs and/or symptoms of airway disorders” (rounded rectangle, top) • “Obtain PFTs and HRCT” (rounded rectangle) • “Airways disorder” (rounded rectangle) • Treatment options (rectangle with numbered list): 1. Asthma/COPD: Manage as per clinical practice guidelines. Inhaled corticosteroids and beta-agonists are the mainstay of management. Avoid anticholinergics to prevent drying of secretions. 2. Bronchiolitis: Trial of inhaled corticosteroids ± macrolides. 3. Nebulized saline and secretagogues in patients with concern for xerotrachea. • “Annual PFTs” (rounded rectangle, bottom) # Connectors : • Downward arrows connect each node sequentially from top to bottom. • No branching; all steps are linear. # Layout : • Vertical, single-column arrangement. • All nodes are aligned centrally, with the treatment options node larger to accommodate the list. # Analysis : • The flowchart presents a stepwise, linear approach for managing airway disorders in Sjögren’s patients: initial assessment, diagnostic testing, confirmation of disorder, tailored treatment based on specific airway condition, and ongoing annual monitoring. No decision branches or alternative pathways are depicted; the process is straightforward and protocol-driven.

I now have comprehensive information from Harrison's 22E, Murray & Nadel's, Fishman's, and GINA 2026. Let me compile a thorough, well-organized response.

Management of Bronchial Asthma

Per Harrison's Principles of Internal Medicine, 22nd Edition (2025) & GINA 2026 Guidelines

Goals of Therapy

Harrison's 22E outlines the following overarching goals:
  1. Achieve and maintain control of symptoms
  2. Prevent recurrent exacerbations (reduce their frequency and severity)
  3. Maintain near-normal lung function (FEV1, PEF)
  4. Maintain normal activity levels including exercise
  5. Avoid adverse effects of asthma medications
  6. Prevent asthma deaths

Assessment of Control (GINA Criteria)

In the past 4 weeks, ask:
  • Daytime symptoms more than twice per week?
  • Night waking due to asthma?
  • Reliever needed more than twice per week?
  • Activity limitation due to asthma?
ScoreControl Level
0 "Yes"Well controlled
1-2 "Yes"Partly controlled
3-4 "Yes"Uncontrolled
Risk factors for poor outcomes include: uncontrolled symptoms, overuse of SABA (>1 canister/month), poor adherence, incorrect inhaler technique, low FEV1 (<60% predicted), obesity, eosinophilia, smoking, lack of ICS. - Murray & Nadel's Textbook of Respiratory Medicine

Asthma Severity Classification (GINA)

SeverityStep Required
MildWell controlled at Step 1 or 2
ModerateWell controlled at Step 3
SevereRequires Step 4-5, or uncontrolled despite it

Step 1 - Reducing Triggers (Non-pharmacologic)

Before or alongside pharmacotherapy (Harrison's 22E):
  • Remove offending exposures: occupational antigens, pets, secondhand smoke, cannabis combustion products
  • Pest control for those with IgE-mediated cockroach/rodent sensitivity
  • Allergen immunotherapy: useful in mild-moderate allergic asthma (SCIT); sublingual evidence weaker
  • Vaccinations: Pneumococcal (regardless of age), annual influenza, COVID-19, RSV vaccine
  • Education: inhaler technique, self-management action plans, trigger avoidance

Stepwise Pharmacologic Management

The Major 2024-2026 Paradigm Shift: ICS-Formoterol as Reliever (AIR Strategy)

Harrison's 22E explains this landmark change clearly:
"A major change in the stepwise approach, advocated for more than two decades, has occurred. Evidence has accumulated that as-needed ICS can be used instead of regular ICS in milder asthma... Since formoterol is a LABA with a rapid onset, combination ICS/formoterol has been used as a single agent in multiple studies: as needed without background therapy in milder asthma... GINA, as part of a comprehensive strategy, recommends ICS/formoterol as the reliever in all steps of asthma severity, including intermittent asthma (step 1)."
GINA now has TWO parallel treatment tracks:
  • Track 1 (Traditional): Regular daily ICS as controller + SABA reliever
  • Track 2 (AIR - Anti-Inflammatory Reliever): ICS-formoterol used as-needed only, without separate daily controller (Step 1-2); or ICS-formoterol daily + as-needed (MART, Step 3-5)
GINA 2026 Update: ICS-SABA combination (e.g., budesonide-albuterol/salbutamol) added as Track 2 alternative at Step 1.

GINA Stepwise Treatment (Adults & Adolescents ≥12 yrs)

StepPreferred ControllerRelieverNotes
Step 1 (Intermittent)None (AIR track) or low-dose ICSAs-needed low-dose ICS-formoterol (preferred) or ICS-SABASABA alone no longer preferred per GINA 2024+
Step 2 (Mild persistent)Low-dose ICS dailyAs-needed low-dose ICS-formoterol or SABA + ICSLTRA alternative if ICS intolerable
Step 3 (Moderate persistent)Low-dose ICS-LABA dailyAs-needed low-dose ICS-formoterol (MART)Medium ICS mono or ICS+LTRA as alternatives
Step 4 (Severe)Medium/high-dose ICS-LABAAs-needed low-dose ICS-formoterolAdd LAMA (tiotropium) if uncontrolled; check technique, adherence
Step 5 (Very severe)High-dose ICS-LABA + LAMAAs-needed ICS-formoterolAdd biologic; consider low-dose OCS
MART (Maintenance and Reliever Therapy): Using same ICS-formoterol inhaler for both scheduled maintenance and as-needed relief. Strong evidence base for budesonide-formoterol.

Pharmacologic Agents in Detail

1. Beta-2 Agonists (Harrison's 22E)

SABAs (Short-Acting Beta-2 Agonists)
  • Salbutamol (albuterol), terbutaline, levalbuterol
  • Rapid onset; peak effect 60-90 min
  • G-protein coupled receptor → ↑cyclic AMP → smooth muscle relaxation
  • Used for acute relief/rescue
  • Regular scheduled SABA use associated with tachyphylaxis, increased airway reactivity - caution
  • Patients needing >2 doses/week should step up therapy
LABAs (Long-Acting Beta-2 Agonists)
  • Salmeterol, formoterol, indacaterol
  • Must NEVER be used as monotherapy in asthma (black box warning - increased mortality)
  • Always combine with ICS
  • Formoterol: rapid onset (~5 min) → suitable as reliever in MART strategy
  • Improve lung function, reduce symptoms, reduce exacerbation frequency

2. Inhaled Corticosteroids (ICS) - Cornerstone

  • Budesonide, fluticasone propionate, beclomethasone, mometasone, ciclesonide
  • Suppress eosinophilic airway inflammation; reduce mucosal edema
  • Most effective anti-inflammatory treatment available
  • All patients with asthma should receive ICS-containing therapy (GINA 2026)
  • Topical side effects: oral candidiasis, dysphonia (use spacer, rinse mouth)
  • Systemic effects minimal at low-medium doses
ICS Dose Equivalents (daily, budesonide-equivalent):
  • Low: ≤400 mcg/day (adults)
  • Medium: 400-800 mcg/day
  • High: >800 mcg/day

3. Leukotriene Receptor Antagonists (LTRAs)

  • Montelukast, zafirlukast
  • Alternative or add-on to ICS at Step 2
  • Useful in aspirin-exacerbated respiratory disease, allergic rhinitis comorbidity, exercise-induced bronchospasm
  • Important caveat (Harrison's 22E): "Recent warnings about suicidal ideation associated with montelukast may make this approach less appealing." - FDA black box warning added in 2020

4. Long-Acting Muscarinic Antagonists (LAMAs)

  • Tiotropium, umeclidinium
  • Step 4-5 add-on therapy
  • GINA 2026 update: Triple therapy (ICS-LABA + LAMA) reduces severe exacerbations vs. ICS-LABA, but reductions are "far less than those achieved with biologic therapy" - useful when biologics are unavailable/contraindicated
  • Tiotropium Respimat approved as add-on for adults ≥12 years

5. Theophylline

  • Weak bronchodilator; narrow therapeutic window
  • Mechanism: phosphodiesterase inhibition → ↑cyclic AMP; anti-inflammatory at low doses
  • Serum level monitoring required (therapeutic: 10-20 mcg/mL; toxic >20 mcg/mL)
  • Step 4-5 adjunct only; largely replaced by LABAs in modern practice
  • Drug interactions (CYP1A2): fluoroquinolones, macrolides, cimetidine increase levels

6. Biologic Agents (Step 5 / Severe Asthma)

Per Harrison's 22E and GINA 2026 - reserved for Type 2 high, eosinophilic, or allergic severe asthma:
BiologicTargetBiomarkerIndication
OmalizumabAnti-IgEElevated serum IgE, allergic sensitizationAllergic asthma ≥6 yrs
MepolizumabAnti-IL-5Blood eos ≥150-300/µLEosinophilic asthma ≥6 yrs
BenralizumabAnti-IL-5RαBlood eos ≥300/µLEosinophilic asthma ≥12 yrs
DupilumabAnti-IL-4Rα (blocks IL-4 + IL-13)Blood eos ≥150/µL or FeNO ≥25 ppbType 2 asthma ≥6 yrs; also COPD with eos + recurrent exacerbations
TezepelumabAnti-TSLPBroad (even non-T2)Severe asthma ≥12 yrs; shows benefit even without elevated biomarkers
DepemokimabAnti-IL-5 (ultra-long-acting)Blood eos ≥300/µLNEW in GINA 2026 - eosinophilic asthma ≥12 yrs; also CRSwNP ≥18 yrs
GINA 2026 additions:
  • Depemokimab (long-acting anti-IL-5, given every 6 months) added as new biologic option
  • Generic anti-IgE (biosimilar omalizumab) added
  • Updated biologic decision tree with clearer guidance

7. Oral Corticosteroids (OCS)

  • Reserved for acute exacerbations and severe/Step 5 asthma
  • GINA 2026 strongly emphasizes minimizing OCS use due to cumulative toxicity
  • Optimize ICS-LABA, address modifiable risk factors, use biologics before resorting to maintenance OCS
  • Short courses (5-7 days prednisolone 30-50 mg/day) for moderate-severe exacerbations

Management of Asthma Exacerbations

Acute Exacerbations - General (Harrison's 22E)

Mild-Moderate Attack:
  • Inhaled SABA up to every 1 hour (or ICS-formoterol as reliever - GINA 2026 new option for mild exacerbations in primary care/ED)
  • Consider increasing ICS dose 4-5 fold
  • If not improving after several hours → urgent care
In Urgent Care Setting:
  • Assess PEFR or FEV1
  • Nebulized beta-2 agonist every 20 minutes
  • Add ipratropium bromide (anticholinergic) - synergistic bronchodilation
  • Add systemic corticosteroids
PEFRAction
>60% predictedOften responds to beta-2 agonists alone
<60% predictedAdd ipratropium + systemic steroids; consider admission
<30% predictedICU-level care, consider IV magnesium
Oxygen therapy (GINA 2026 update):
  • Do NOT give supplemental O2 unless SpO2 <92%
  • Target SpO2: 93-95% (adults, adolescents, children 6-11 yrs)
  • Target SpO2: ≥92% (children ≤5 yrs with severe exacerbation)

Severe/Near-Fatal Acute Asthma

Per Harrison's 22E:
  • Admit to ICU if PEFR <30% predicted, life-threatening features, or failure to respond
  • High-dose inhaled + systemic bronchodilators
  • IV methylprednisolone
  • Controlled oxygen (titrate to target)
  • Consider IV magnesium sulfate (2g over 20 min) - relaxes airway smooth muscle via calcium antagonism
  • Heliox (helium-oxygen mixture) - reduces turbulent airflow in critical obstruction
  • Non-invasive positive pressure ventilation (NIPPV) in selected patients
  • Mechanical ventilation if respiratory failure imminent: use permissive hypercapnia, low tidal volumes (5-7 mL/kg), prolonged expiratory time, avoid auto-PEEP
Discharge criteria: PEFR >60%, symptoms controlled, inhaler technique confirmed, follow-up arranged within 1-2 weeks.

GINA 2026 - Key New Updates (May 2026)

  1. ICS-SABA combination as Track 2 reliever at Step 1 (new alternative to ICS-formoterol)
  2. ICS-formoterol as alternate to SABA for mild exacerbations in primary care/ED
  3. Depemokimab added as new biologic (anti-IL-5, every 6-month dosing)
  4. Revised oxygen targets: O2 only if SpO2 <92%; target 93-95% for adults
  5. New flowcharts for primary care management of exacerbations (adults, children 6-11, children ≤5)
  6. Anaphylaxis protocol: If anaphylaxis + asthma features co-present → give epinephrine FIRST, then bronchodilators
  7. Triple therapy clarification: ICS-LABA + LAMA reduces exacerbations vs. ICS-LABA, but less so than biologics; use when biologics unavailable
  8. OCS minimization strongly emphasized
  9. Vaccine updates: Evidence updated for influenza, RSV, COVID-19 vaccines
  10. GLP-1 receptor agonists: New observational data on potential role in improving asthma outcomes
  11. New assessment tools: CAAT (Chronic Airways Assessment Test), Peds-AIRQ, PRAM added

Special Populations (Harrison's 22E)

Elderly Patients

  • Mortality 5x higher than younger cohorts
  • Adjust step therapy for β2-agonist intolerance (arrhythmias, tremulousness)
  • Always consider COPD coexistence
  • New-onset asthma in elderly: ~50% are/were smokers; ~25% occupational etiology

Asthma-COPD Overlap

  • Smoking blunts ICS response
  • Dupilumab effective in COPD with elevated eosinophils + recurrent exacerbations
  • Earlier initiation of LAMAs may be beneficial

Severe Refractory Asthma (~5-10% of all asthma)

  • Definition: Uncontrolled despite Step 5, OR requires Step 5 for control, after ruling out mimics, addressing comorbidities, and confirming adherence/technique
  • 50% have persistent eosinophilic inflammation
  • Biologic therapies (anti-IL-5, anti-IgE, anti-IL-4Rα, anti-TSLP) are the primary option
  • Macrolides (azithromycin) useful in a subset (likely non-eosinophilic/neutrophilic)
  • Bronchial thermoplasty: bronchoscopic option - reduces airway smooth muscle mass

Inhaler Device Selection

Per Fishman's Pulmonary Diseases and Disorders: Inhaled therapy is the cornerstone. Selection based on:
  1. Clinical condition and disease severity
  2. Patient's ability to use the device correctly
  3. Availability and cost
  4. Patient/prescriber preference
DeviceProsCons
pMDICompact, portable, cheap, multidoseNeeds hand-mouth coordination; oropharyngeal deposition
pMDI + spacerRemoves coordination need; less oropharyngeal depositionBulkier
DPIBreath-actuated, no coordination neededNeeds adequate inspiratory flow; humidity sensitive
NebulizerGood for acute/severe, elderly, young childrenBulky, time-consuming, expensive
GINA 2026 note: For pMDIs formulated as suspensions (salbutamol, budesonide-formoterol, fluticasone-salmeterol) - shake immediately before each actuation.

Monitoring and Follow-up

  • Reassess control at every visit (4-question GINA tool)
  • Spirometry/PEFR monitoring
  • Verify inhaler technique at every visit
  • Review adherence
  • Assess and manage comorbidities (allergic rhinitis, GERD, obesity, OSA, anxiety/depression)
  • Consider stepping down therapy if well-controlled for ≥3 months (never step down during pregnancy or high-risk season)
  • FeNO: useful to identify eosinophilic airway inflammation and predict steroid response

Summary Image - Stepwise Treatment Continuum

Asthma stepwise management continuum
Key Sources:

Create a concise clinical summary document for easy reference

Reading File
Running Command

ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace && echo "workspace ready"

Running Command

mkdir -p /tmp/workspace/asthma-summary && cat > /tmp/workspace/asthma-summary/create_doc.py << 'PYEOF' from docx import Document from docx.shared import Pt, Inches, RGBColor from docx.enum.text import WD_ALIGN_PARAGRAPH from docx.oxml.ns import qn from docx.oxml import OxmlElement import copy doc = Document() # ── Page margins ────────────────────────────────────────────────── section = doc.sections[0] section.page_width = Inches(8.5) section.page_height = Inches(11) section.top_margin = Inches(0.75) section.bottom_margin = Inches(0.75) section.left_margin = Inches(0.85) section.right_margin = Inches(0.85) # ── Base style ──────────────────────────────────────────────────── normal = doc.styles["Normal"] normal.font.name = "Calibri" normal.font.size = Pt(9.5) # ── Colour palette ──────────────────────────────────────────────── NAVY = RGBColor(0x1A, 0x35, 0x5E) # headings TEAL = RGBColor(0x00, 0x7A, 0x87) # sub-headings RED = RGBColor(0xC0, 0x39, 0x2B) # warnings / alerts GREEN = RGBColor(0x1E, 0x7A, 0x45) # positive / new GREY = RGBColor(0xF2, 0xF5, 0xF7) # table header fill WHITE = RGBColor(0xFF, 0xFF, 0xFF) BLACK = RGBColor(0x00, 0x00, 0x00) # ── Helper: set cell background ─────────────────────────────────── def set_cell_bg(cell, rgb: RGBColor): tc = cell._tc tcPr = tc.get_or_add_tcPr() shd = OxmlElement("w:shd") hex6 = f"{rgb[0]:02X}{rgb[1]:02X}{rgb[2]:02X}" shd.set(qn("w:val"), "clear") shd.set(qn("w:color"), "auto") shd.set(qn("w:fill"), hex6) tcPr.append(shd) def set_cell_borders(cell, border_color="999999", border_sz="4"): tc = cell._tc tcPr = tc.get_or_add_tcPr() tcBorders = OxmlElement("w:tcBorders") for side in ["top","left","bottom","right"]: b = OxmlElement(f"w:{side}") b.set(qn("w:val"), "single") b.set(qn("w:sz"), border_sz) b.set(qn("w:space"), "0") b.set(qn("w:color"), border_color) tcBorders.append(b) tcPr.append(tcBorders) def para_spacing(para, before=0, after=60): pPr = para._p.get_or_add_pPr() spacing = OxmlElement("w:spacing") spacing.set(qn("w:before"), str(before)) spacing.set(qn("w:after"), str(after)) pPr.append(spacing) # ── Helper: coloured heading ────────────────────────────────────── def add_heading(text, level=1, color=NAVY, size=13, bold=True, before=120, after=40): p = doc.add_paragraph() para_spacing(p, before=before, after=after) run = p.add_run(text) run.bold = True run.font.color.rgb = color run.font.size = Pt(size) run.font.name = "Calibri" return p def add_sub(text, color=TEAL, size=10, bold=True): p = doc.add_paragraph() para_spacing(p, before=60, after=20) run = p.add_run(text) run.bold = bold run.font.color.rgb = color run.font.size = Pt(size) run.font.name = "Calibri" return p def add_body(text, bold_prefix=None, color=BLACK, size=9.5, indent=False): p = doc.add_paragraph() para_spacing(p, before=0, after=30) if indent: pPr = p._p.get_or_add_pPr() ind = OxmlElement("w:ind") ind.set(qn("w:left"), "200") pPr.append(ind) if bold_prefix: r = p.add_run(bold_prefix + " ") r.bold = True r.font.size = Pt(size) r.font.name = "Calibri" r.font.color.rgb = color r2 = p.add_run(text) r2.font.size = Pt(size) r2.font.name = "Calibri" r2.font.color.rgb = color return p def add_bullet(text, bold_prefix=None, level=0): p = doc.add_paragraph(style="List Bullet") para_spacing(p, before=0, after=18) if bold_prefix: r = p.add_run(bold_prefix + " ") r.bold = True r.font.size = Pt(9.5) r.font.name = "Calibri" r2 = p.add_run(text) r2.font.size = Pt(9.5) r2.font.name = "Calibri" return p def add_alert(text, color=RED, size=9.5): p = doc.add_paragraph() para_spacing(p, before=40, after=40) pPr = p._p.get_or_add_pPr() # left border pBdr = OxmlElement("w:pBdr") left = OxmlElement("w:left") left.set(qn("w:val"), "thick") left.set(qn("w:sz"), "18") left.set(qn("w:space"), "8") left.set(qn("w:color"), f"{color[0]:02X}{color[1]:02X}{color[2]:02X}") pBdr.append(left) pPr.append(pBdr) r = p.add_run(text) r.bold = True r.font.color.rgb = color r.font.size = Pt(size) r.font.name = "Calibri" return p # ══════════════════════════════════════════════════════════════════ # TITLE BLOCK # ══════════════════════════════════════════════════════════════════ title_p = doc.add_paragraph() para_spacing(title_p, before=0, after=20) tr = title_p.add_run("BRONCHIAL ASTHMA — Clinical Management Summary") tr.bold = True tr.font.size = Pt(15) tr.font.color.rgb = WHITE tr.font.name = "Calibri" # set para shading (navy banner) pPr2 = title_p._p.get_or_add_pPr() shd2 = OxmlElement("w:shd") shd2.set(qn("w:val"), "clear") shd2.set(qn("w:color"), "auto") shd2.set(qn("w:fill"), "1A355E") pPr2.append(shd2) title_p.alignment = WD_ALIGN_PARAGRAPH.CENTER sub_p = doc.add_paragraph() para_spacing(sub_p, before=0, after=60) sr = sub_p.add_run("Based on Harrison's 22E (2025) · GINA 2026 · Murray & Nadel's · Fishman's") sr.italic = True sr.font.size = Pt(8.5) sr.font.color.rgb = RGBColor(0x55, 0x55, 0x55) sr.font.name = "Calibri" sub_p.alignment = WD_ALIGN_PARAGRAPH.CENTER # ══════════════════════════════════════════════════════════════════ # 1. ASSESSMENT OF CONTROL # ══════════════════════════════════════════════════════════════════ add_heading("1. ASSESSMENT OF SYMPTOM CONTROL (GINA 4-Question Tool)", level=1, size=11) tbl = doc.add_table(rows=1, cols=3) tbl.style = "Table Grid" hdr = tbl.rows[0].cells for i, txt in enumerate(["Question (past 4 weeks)", "Yes", "No"]): hdr[i].text = txt hdr[i].paragraphs[0].runs[0].bold = True hdr[i].paragraphs[0].runs[0].font.size = Pt(9) set_cell_bg(hdr[i], NAVY) hdr[i].paragraphs[0].runs[0].font.color.rgb = WHITE rows_data = [ "Daytime symptoms >2×/week?", "Night waking due to asthma?", "Reliever needed >2×/week?", "Any activity limitation?", ] for q in rows_data: row = tbl.add_row().cells row[0].text = q row[0].paragraphs[0].runs[0].font.size = Pt(9) set_cell_bg(row[1], RGBColor(0xF8,0xF8,0xF8)) set_cell_bg(row[2], RGBColor(0xF8,0xF8,0xF8)) # score legend score_row = tbl.add_row().cells score_row[0].merge(score_row[2]) score_row[0].text = "0 Yes = Well controlled | 1–2 Yes = Partly controlled | 3–4 Yes = Uncontrolled" sr2 = score_row[0].paragraphs[0].runs[0] sr2.bold = True sr2.font.size = Pt(9) set_cell_bg(score_row[0], RGBColor(0xE8,0xF4,0xFD)) doc.add_paragraph() # Risk factors box add_sub("Risk Factors for Poor Outcomes") risks = [ "Uncontrolled symptoms / ≥1 severe exacerbation in past year", "SABA overuse (>1 canister/month) — marker of poor control", "No ICS, poor adherence, or incorrect inhaler technique", "FEV1 <60% predicted or high bronchodilator reversibility", "Comorbidities: obesity, chronic rhinosinusitis, GERD, depression", "Smoking, occupational exposure, indoor allergens", "Blood eosinophilia / elevated FeNO", ] for r in risks: add_bullet(r) doc.add_paragraph() # ══════════════════════════════════════════════════════════════════ # 2. SEVERITY CLASSIFICATION # ══════════════════════════════════════════════════════════════════ add_heading("2. SEVERITY CLASSIFICATION (GINA)", level=1, size=11) sev_tbl = doc.add_table(rows=1, cols=2) sev_tbl.style = "Table Grid" for i, h in enumerate(["Severity", "Definition"]): sev_tbl.rows[0].cells[i].text = h sev_tbl.rows[0].cells[i].paragraphs[0].runs[0].bold = True sev_tbl.rows[0].cells[i].paragraphs[0].runs[0].font.size = Pt(9) set_cell_bg(sev_tbl.rows[0].cells[i], TEAL) sev_tbl.rows[0].cells[i].paragraphs[0].runs[0].font.color.rgb = WHITE for sev, defn in [ ("Mild", "Well controlled on Step 1 or Step 2"), ("Moderate", "Well controlled on Step 3"), ("Severe", "Requires Step 4–5 to maintain control, OR uncontrolled despite Step 4–5"), ]: row = sev_tbl.add_row().cells row[0].text = sev row[0].paragraphs[0].runs[0].font.size = Pt(9) row[0].paragraphs[0].runs[0].bold = True row[1].text = defn row[1].paragraphs[0].runs[0].font.size = Pt(9) doc.add_paragraph() # ══════════════════════════════════════════════════════════════════ # 3. STEPWISE TREATMENT # ══════════════════════════════════════════════════════════════════ add_heading("3. STEPWISE PHARMACOLOGIC MANAGEMENT (Adults & Adolescents ≥12 yrs)", level=1, size=11) add_alert("⚑ GINA 2026 PARADIGM SHIFT: SABA monotherapy is NO LONGER preferred at any step.\n" " All patients should receive ICS-containing therapy. ICS-formoterol is the preferred reliever at every step.") doc.add_paragraph() step_tbl = doc.add_table(rows=1, cols=5) step_tbl.style = "Table Grid" step_hdrs = ["Step", "Severity", "Controller (Daily)", "Reliever (As-needed)", "Notes"] for i, h in enumerate(step_hdrs): c = step_tbl.rows[0].cells[i] c.text = h c.paragraphs[0].runs[0].bold = True c.paragraphs[0].runs[0].font.size = Pt(8.5) set_cell_bg(c, NAVY) c.paragraphs[0].runs[0].font.color.rgb = WHITE steps = [ ("1", "Intermittent", "None (AIR track)\nOR Low-dose ICS daily", "As-needed low-dose ICS-formoterol ★\nOR ICS-SABA combo (new 2026)\n[SABA alone: no longer preferred]", "AIR = Anti-Inflammatory Reliever strategy"), ("2", "Mild\nPersistent", "Low-dose ICS daily", "As-needed low-dose ICS-formoterol ★\nOR SABA + concurrent ICS\nAlt: LTRA if ICS intolerable", "Caution: montelukast — FDA black-box warning (suicidal ideation)"), ("3", "Moderate\nPersistent", "Low-dose ICS-LABA\n(preferred)\nAlt: Medium ICS or ICS+LTRA", "As-needed low-dose ICS-formoterol\n(MART strategy ★★)", "MART: same inhaler for maintenance + relief\n(budesonide-formoterol)"), ("4", "Severe", "Medium/High-dose ICS-LABA\n+ consider add-on LAMA", "As-needed low-dose ICS-formoterol", "Check adherence & inhaler technique first\nRefer to specialist"), ("5", "Very Severe\n/ Refractory", "High-dose ICS-LABA + LAMA\n+ Biologic therapy\n(see biologic table)", "As-needed ICS-formoterol", "Minimize/avoid maintenance OCS\nBronchial thermoplasty option"), ] row_fills = [RGBColor(0xEA,0xF4,0xEA), RGBColor(0xFF,0xFF,0xE8), RGBColor(0xFD,0xF0,0xD8), RGBColor(0xFD,0xE8,0xE8), RGBColor(0xF5,0xE8,0xF5)] for idx, (step, sev, ctrl, rel, note) in enumerate(steps): row = step_tbl.add_row().cells for ci, txt in enumerate([step, sev, ctrl, rel, note]): row[ci].text = txt for run in row[ci].paragraphs[0].runs: run.font.size = Pt(8.5) set_cell_bg(row[ci], row_fills[idx]) row[0].paragraphs[0].runs[0].bold = True row[0].paragraphs[0].runs[0].font.size = Pt(10) p_note = doc.add_paragraph() para_spacing(p_note, before=20, after=20) rn = p_note.add_run("★ ICS-formoterol (e.g., budesonide/formoterol) preferred reliever across all steps per GINA 2026 " "★★ MART = Maintenance And Reliever Therapy") rn.italic = True rn.font.size = Pt(8) rn.font.color.rgb = RGBColor(0x44,0x44,0x44) doc.add_paragraph() # ══════════════════════════════════════════════════════════════════ # 4. DRUG CLASSES # ══════════════════════════════════════════════════════════════════ add_heading("4. KEY DRUG CLASSES", level=1, size=11) drug_tbl = doc.add_table(rows=1, cols=4) drug_tbl.style = "Table Grid" for i, h in enumerate(["Drug Class", "Examples", "Mechanism / Role", "Key Cautions"]): c = drug_tbl.rows[0].cells[i] c.text = h c.paragraphs[0].runs[0].bold = True c.paragraphs[0].runs[0].font.size = Pt(9) set_cell_bg(c, TEAL) c.paragraphs[0].runs[0].font.color.rgb = WHITE drug_rows = [ ("SABA", "Salbutamol, Terbutaline", "β2 activation → ↑cAMP → smooth muscle relaxation\nRelief/rescue; PRN use", "Overuse (>1 can/month) = poor control marker\nTachyphylaxis with scheduled use"), ("LABA", "Formoterol, Salmeterol, Indacaterol", "Long-acting β2 agonist; combine with ICS\nFormoterol: rapid onset → suitable for MART", "NEVER monotherapy in asthma\n(↑mortality — black box warning)"), ("ICS", "Budesonide, Fluticasone, Beclomethasone, Mometasone", "Suppress eosinophilic inflammation\nCornerstoneof all asthma therapy", "Oral candidiasis, dysphonia\n→ use spacer, rinse mouth after"), ("ICS-LABA\nCombination", "Budesonide/formoterol\nFluticasone/salmeterol\nFluticasone/vilanterol", "Dual controller; MART possible with\nbudesonide/formoterol", "Preferred combination at Steps 3–5"), ("LAMA", "Tiotropium (Respimat)\nUmeclidinium", "Long-acting muscarinic antagonist\nAdd-on at Steps 4–5", "Triple Rx (ICS-LABA+LAMA) < biologics\nfor reducing severe exacerbations"), ("LTRA", "Montelukast, Zafirlukast", "Leukotriene receptor antagonist\nAlt/add-on; useful in AERD, allergic rhinitis", "⚠ Montelukast: FDA black box — suicidal ideation/behaviour"), ("Theophylline", "Aminophylline (IV)\nTheophylline (oral)", "PDE inhibition → ↑cAMP; anti-inflammatory\nNarrow therapeutic window", "Serum level: 10–20 mcg/mL\nDrug interactions: fluoroquinolones, macrolides"), ("OCS", "Prednisolone\nMethylprednisolone (IV)", "Acute: short courses 5–7 days, 30–50 mg/day\nChronic: only if all else fails", "Minimize long-term use\nCumulative toxicity: T2DM, osteoporosis, cataracts"), ] alt_fill = [RGBColor(0xFF,0xFF,0xFF), RGBColor(0xF7,0xF9,0xFC)] for idx, row_data in enumerate(drug_rows): row = drug_tbl.add_row().cells for ci, txt in enumerate(row_data): row[ci].text = txt for run in row[ci].paragraphs[0].runs: run.font.size = Pt(8.5) set_cell_bg(row[ci], alt_fill[idx % 2]) doc.add_paragraph() # ══════════════════════════════════════════════════════════════════ # 5. BIOLOGICS # ══════════════════════════════════════════════════════════════════ add_heading("5. BIOLOGIC AGENTS (Step 5 — Severe / Type 2 Asthma)", level=1, size=11) bio_tbl = doc.add_table(rows=1, cols=5) bio_tbl.style = "Table Grid" for i, h in enumerate(["Biologic", "Target", "Biomarker Threshold", "Age", "Notes"]): c = bio_tbl.rows[0].cells[i] c.text = h c.paragraphs[0].runs[0].bold = True c.paragraphs[0].runs[0].font.size = Pt(9) set_cell_bg(c, NAVY) c.paragraphs[0].runs[0].font.color.rgb = WHITE bio_rows = [ ("Omalizumab\n(biosimilar available)", "Anti-IgE", "Elevated serum IgE\n+ allergic sensitization", "≥6 yrs", "Allergic/atopic asthma\nMonthly or bimonthly SC"), ("Mepolizumab", "Anti-IL-5", "Blood eos ≥150–300/μL", "≥6 yrs", "Eosinophilic asthma\nMonthly SC"), ("Benralizumab", "Anti-IL-5Rα", "Blood eos ≥300/μL", "≥12 yrs", "Eosinophilic; Q8 weekly SC\nafter 3 monthly loading doses"), ("Dupilumab", "Anti-IL-4Rα\n(blocks IL-4 + IL-13)", "Blood eos ≥150/μL\nOR FeNO ≥25 ppb", "≥6 yrs", "Type 2 asthma; also approved\nfor COPD with eos + exacerbations"), ("Tezepelumab", "Anti-TSLP\n(upstream cytokine)", "Broad; works even without\nelevated T2 biomarkers", "≥12 yrs", "Severe asthma including\nnon-Type 2 phenotype"), ("Depemokimab ★NEW", "Anti-IL-5\n(ultra-long-acting)", "Blood eos ≥300/μL", "≥12 yrs\n(CRSwNP ≥18)", "NEW — GINA 2026\nDosing every 6 months SC"), ] for idx, row_data in enumerate(bio_rows): row = bio_tbl.add_row().cells for ci, txt in enumerate(row_data): row[ci].text = txt for run in row[ci].paragraphs[0].runs: run.font.size = Pt(8.5) set_cell_bg(row[ci], alt_fill[idx % 2]) doc.add_paragraph() # ══════════════════════════════════════════════════════════════════ # 6. ACUTE EXACERBATION MANAGEMENT # ══════════════════════════════════════════════════════════════════ add_heading("6. ACUTE EXACERBATION MANAGEMENT", level=1, size=11) add_sub("Initial Assessment — PEFR/FEV1 Classification") pefr_tbl = doc.add_table(rows=1, cols=4) pefr_tbl.style = "Table Grid" for i, h in enumerate(["Severity", "PEFR", "Features", "Immediate Action"]): c = pefr_tbl.rows[0].cells[i] c.text = h c.paragraphs[0].runs[0].bold = True c.paragraphs[0].runs[0].font.size = Pt(9) set_cell_bg(c, TEAL) c.paragraphs[0].runs[0].font.color.rgb = WHITE pefr_rows = [ ("Mild–Moderate", ">60% predicted", "Wheeze, SOB; speaks in sentences\nSpO2 ≥92%", "Inhaled SABA q20 min ×3 (or ICS-formoterol)\nMonitor, OCS if no response in 1–2h"), ("Severe", "40–60% predicted", "Speaks in words; accessory muscle use\nSpO2 <92%", "SABA + ipratropium q20 min ×3\nSystemic OCS\nControlled O2 (target SpO2 93–95%)"), ("Life-Threatening", "<40% predicted", "Silent chest, cyanosis, altered consciousness\nPEFR <30% = ICU", "IV methylprednisolone\nIV/nebulized bronchodilators\nIV MgSO4 2g over 20 min\nConsider intubation"), ] exac_fills = [RGBColor(0xEA,0xF7,0xEA), RGBColor(0xFF,0xF3,0xCC), RGBColor(0xFD,0xE8,0xE8)] for idx, row_data in enumerate(pefr_rows): row = pefr_tbl.add_row().cells for ci, txt in enumerate(row_data): row[ci].text = txt for run in row[ci].paragraphs[0].runs: run.font.size = Pt(8.5) set_cell_bg(row[ci], exac_fills[idx]) doc.add_paragraph() add_alert("⚑ O2 THERAPY (GINA 2026): Supplemental O2 ONLY if SpO2 <92%\n" " Target: 93–95% (adults, adolescents, children 6–11 yrs) | ≥92% (children ≤5 yrs)\n" " ⚑ ANAPHYLAXIS + ASTHMA: Give EPINEPHRINE first, then bronchodilators") doc.add_paragraph() add_sub("ICU / Ventilated Patient") icu_bullets = [ "Permissive hypercapnia acceptable (avoid barotrauma)", "Low tidal volumes 5–7 mL/kg ideal body weight", "Prolonged expiratory time; minimise auto-PEEP", "Heliox (He:O2 70:30) — reduces turbulent airflow in critical obstruction", "IV ketamine: bronchodilatory anaesthetic induction agent", "Avoid propofol-only without ICS if reactive airways", ] for b in icu_bullets: add_bullet(b) doc.add_paragraph() add_sub("Discharge Criteria") dc = [ "PEFR ≥60% predicted (ideally ≥70–80%)", "Symptoms controlled; no nocturnal symptoms", "Inhaler technique verified", "Written asthma action plan provided", "Follow-up arranged within 1–2 weeks", "Prednisolone course completed or continued as prescribed", ] for d in dc: add_bullet(d) doc.add_paragraph() # ══════════════════════════════════════════════════════════════════ # 7. GINA 2026 KEY UPDATES # ══════════════════════════════════════════════════════════════════ add_heading("7. GINA 2026 — KEY NEW UPDATES (May 5, 2026)", level=1, size=11, color=GREEN, before=80) updates = [ ("ICS-SABA combo at Step 1:", "Added as Track 2 (AIR) alternative to ICS-formoterol at Step 1"), ("ICS-formoterol in mild exacerbations:", "Now an alternate to inhaled SABA in primary care / ED (adults, adolescents, children 6–11)"), ("Depemokimab:", "New biologic (anti-IL-5, every-6-month dosing) added for severe eosinophilic asthma ≥12 yrs"), ("Biosimilar omalizumab:", "Generic anti-IgE added as biologic option"), ("O2 thresholds revised:", "O2 only if SpO2 <92%; target 93–95% adults; ≥92% for children ≤5 yrs"), ("Anaphylaxis protocol:", "If anaphylaxis + asthma co-present → epinephrine FIRST, then bronchodilators"), ("Triple therapy clarification:", "ICS-LABA + LAMA reduces exacerbations vs ICS-LABA, but far less than biologics"), ("OCS minimization:", "Strongly emphasized — optimize ICS-LABA, modifiable factors, and biologics before maintenance OCS"), ("New assessment tools:", "CAAT, Peds-AIRQ, PRAM added to guideline toolkit"), ("Vaccines:", "Evidence updated for influenza, RSV, and COVID-19 vaccines in asthma"), ("GLP-1 receptor agonists:", "Observational data added on potential role in improving asthma outcomes (future direction)"), ("New flowcharts:", "4 new flowcharts for primary care / ED management of exacerbations by age group"), ] for bold_t, body_t in updates: add_bullet(body_t, bold_prefix=bold_t) doc.add_paragraph() # ══════════════════════════════════════════════════════════════════ # 8. SPECIAL POPULATIONS # ══════════════════════════════════════════════════════════════════ add_heading("8. SPECIAL POPULATIONS", level=1, size=11) sp_tbl = doc.add_table(rows=1, cols=2) sp_tbl.style = "Table Grid" for i, h in enumerate(["Population", "Key Considerations"]): c = sp_tbl.rows[0].cells[i] c.text = h c.paragraphs[0].runs[0].bold = True c.paragraphs[0].runs[0].font.size = Pt(9) set_cell_bg(c, TEAL) c.paragraphs[0].runs[0].font.color.rgb = WHITE sp_rows = [ ("Elderly (>65 yrs)", "5× higher mortality than younger patients\nAdjust β2-agonist dose for arrhythmia/tremulousness\nAlways consider COPD coexistence\nNew-onset: ~50% are/were smokers; ~25% occupational aetiology"), ("Asthma-COPD Overlap", "Smoking blunts ICS response\nDupilumab approved in COPD with eos + recurrent exacerbations\nEarlier initiation of LAMAs beneficial"), ("Severe Refractory\n(~5–10% of asthma)", "Uncontrolled on Step 5 after confirming adherence, technique, and treating comorbidities\n>50% have persistent eosinophilic inflammation\nMacrolides useful in neutrophilic/non-eosinophilic subset\nBronchial thermoplasty: bronchoscopic option — reduces airway smooth muscle mass"), ("Pregnancy", "Uncontrolled asthma more dangerous than ICS therapy\nContinue ICS; avoid stepping down\nSalbutamol safe as reliever; budesonide preferred ICS"), ("Exercise-Induced", "Pre-exercise SABA or ICS-formoterol 15 min before\nRegular ICS reduces EIB\nLTRA useful adjunct"), ("Aspirin/NSAID-Exacerbated\n(AERD)", "Avoid NSAIDs, aspirin\nLTRA particularly useful\nAspirin desensitisation under specialist supervision"), ] for idx, row_data in enumerate(sp_rows): row = sp_tbl.add_row().cells for ci, txt in enumerate(row_data): row[ci].text = txt for run in row[ci].paragraphs[0].runs: run.font.size = Pt(8.5) set_cell_bg(row[ci], alt_fill[idx % 2]) doc.add_paragraph() # ══════════════════════════════════════════════════════════════════ # 9. NON-PHARMACOLOGIC / MONITORING # ══════════════════════════════════════════════════════════════════ add_heading("9. NON-PHARMACOLOGIC MEASURES & MONITORING", level=1, size=11) left_items = [ ("Trigger avoidance:", "Remove pets, occupational antigens, second-hand smoke, cannabis"), ("Allergen immunotherapy:", "Mild–moderate allergic asthma; SCIT under controlled conditions"), ("Vaccinations:", "Annual influenza; pneumococcal; COVID-19; RSV"), ("Inhaler education:", "Technique check at every visit — poor technique in up to 50% of 'refractory' cases"), ("Written action plan:", "Green/yellow/red zones based on PEFR or symptoms"), ("FeNO monitoring:", "≥25 ppb = eosinophilic inflammation; predicts ICS response"), ("Weight loss / OSA:", "Obesity worsens control; screen and treat OSA"), ("Rhinosinusitis / GERD:", "Manage upper airway disease and reflux as asthma comorbidities"), ] for bold_t, body_t in left_items: add_bullet(body_t, bold_prefix=bold_t) doc.add_paragraph() # ══════════════════════════════════════════════════════════════════ # FOOTER # ══════════════════════════════════════════════════════════════════ footer_p = doc.add_paragraph() para_spacing(footer_p, before=60, after=0) pPr3 = footer_p._p.get_or_add_pPr() shd3 = OxmlElement("w:shd") shd3.set(qn("w:val"), "clear") shd3.set(qn("w:color"), "auto") shd3.set(qn("w:fill"), "1A355E") pPr3.append(shd3) footer_r = footer_p.add_run( "Sources: Harrison's Principles of Internal Medicine 22E (2025, McGraw-Hill) · " "GINA 2026 Strategy Report (May 5 2026, ginasthma.org) · " "Murray & Nadel's Textbook of Respiratory Medicine · " "Fishman's Pulmonary Diseases & Disorders | Prepared: August 2026" ) footer_r.font.size = Pt(7.5) footer_r.font.color.rgb = WHITE footer_r.font.name = "Calibri" footer_p.alignment = WD_ALIGN_PARAGRAPH.CENTER # ── Save ────────────────────────────────────────────────────────── out = "/tmp/workspace/asthma-summary/Asthma_Clinical_Summary.docx" doc.save(out) print(f"SAVED: {out}") PYEOF python3 /tmp/workspace/asthma-summary/create_doc.py

Running Command

python3 -c " from docx import Document doc = Document('/tmp/workspace/asthma-summary/Asthma_Clinical_Summary.docx') headings = [p.text for p in doc.paragraphs if p.text.strip() and len(p.text) > 5][:30] print('Paragraphs preview:') for h in headings: print(' -', h[:90]) import os size = os.path.getsize('/tmp/workspace/asthma-summary/Asthma_Clinical_Summary.docx') print(f'File size: {size:,} bytes') "

Your clinical summary document is ready:

Asthma Clinical Summary

Word Document · DOCX

What's inside (9 sections, colour-coded tables throughout):
SectionContents
1. Symptom Control AssessmentGINA 4-question tool table + risk factors for poor outcomes
2. Severity ClassificationMild / Moderate / Severe defined by treatment step
3. Stepwise TreatmentStep 1-5 table with colour-coded rows — controller, reliever, and notes per step; GINA 2026 paradigm shift callout box
4. Drug ClassesSABA, LABA, ICS, ICS-LABA, LAMA, LTRA, Theophylline, OCS — mechanism, examples, key cautions
5. BiologicsAll 6 agents (incl. Depemokimab - new 2026) — target, biomarker threshold, age, notes
6. Acute ExacerbationPEFR severity table, revised O2 targets, ICU/ventilation tips, discharge criteria
7. GINA 2026 Updates12 key changes highlighted with bold prefixes
8. Special PopulationsElderly, asthma-COPD overlap, refractory, pregnancy, exercise-induced, AERD
9. Non-pharmacologic & MonitoringTrigger avoidance, vaccination, FeNO, written action plans, comorbidities
The document uses a navy/teal colour scheme with alert boxes for warnings, formatted for A4/letter printing or on-screen reference.
This is a shared conversation. Sign in to Orris to start your own chat.